menu search

Britain approves first oral covid-19 antiviral from merck

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization to Merck & Co Inc (NYSE: MRK) and Ridgeba...

November 4, 2021, 6:56 am

Merck files for emergency authorization of covid-19-treating pill

Merck & Co. Inc. MRK, -1.60% and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) w...

October 11, 2021, 6:14 am

Merck files for emergency authorization of covid-19-treating pill

Merck & Co. Inc. MRK, -1.60% and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) w...

October 11, 2021, 6:14 am

Merck files for emergency authorization of covid-19-treating pill

Merck & Co. Inc. MRK, -1.60% and Ridgeback Biotherapeutics said Monday that Merck has submitted an application for Emergency Use Authorization (EUA) w...

October 11, 2021, 6:14 am

Else nutrition receives key us patent notice of allowance for use in functional food

Else Nutrition Holdings Inc, the plant-based baby, toddler and children nutrition company, announced that it has just received a US Notice of Allowanc...

October 8, 2021, 8:39 am

Else nutrition receives key us patent notice of allowance for use in functional food

Else Nutrition Holdings Inc, the plant-based baby, toddler and children nutrition company, announced that it has just received a US Notice of Allowanc...

October 8, 2021, 8:39 am

Else nutrition receives key us patent notice of allowance for use in functional food

Else Nutrition Holdings Inc, the plant-based baby, toddler and children nutrition company, announced that it has just received a US Notice of Allowanc...

October 8, 2021, 8:39 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Eledon pharmaceuticals announces presentation on at-1501 at the virtual 2021 northeast amyotrophic lateral sclerosis consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical compa...

October 7, 2021, 7:51 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am

Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021

Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...

October 5, 2021, 1:00 am


Search within

Pages Search Results: